Clinical Pipeline Leverage Cognition Therapeutics high-potential zervimesine (CT1812) as a first-in-class oral therapy targeting neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies to position partnerships or licensing discussions with larger biopharma seeking late-stage neurodegenerative assets.

Clinical Momentum With ongoing Phase 2 SHINE results and presentations at AD/PD and AAIC and a track record of biomarker data sharing, there is credibility for collaborating with contract research organizations, academic consortia, or investors looking to back translational neurodegeneration programs.

Strategic Partnerships Cognition’s focus on mechanistic, translational science and two decades of research creates opportunities for co-development, out-licensing, or joint ventures with specialty pharma companies aiming to accelerate neurodegenerative therapeutics to underserved patient populations.

Financial Leverage With substantial funding of over $200M and a Nasdaq-listed profile, there is potential for strategic financing, milestone-based investments, or collaboration with financial partners to scale late-stage development and commercial readiness.

Engaged Stakeholders Active participation of CEO Lisa Ricciardi in investor-focused events and key conferences indicates a readiness to explore partnerships with investors, clinical CROs, and patient advocacy groups to expand market access discussions and real-world evidence generation.